Trajectory of Serum Albumin Prior to Death in Patients Receiving Hemodialysis

Published:August 22, 2022DOI:


      Although some clinical expert guidelines recommend regular monitoring of serum albumin levels in patients undergoing maintenance hemodialysis, little is known about the serum albumin trajectory patterns over time, and it is unclear how the trajectory change before death.


      We performed this retrospective study using data from 421 patients receiving hemodialysis in a dialysis facility. We divided patients into died and survived groups according to whether they died during the observation period. To compare the albumin trajectories during the observation period between the died and survived groups, linear mixed-effect models and a backward timescale from the year of death or study end were used.


      During the observation period (median, 5.1 years; maximum, 8.4 years), 115 patients receiving dialysis died. The serum albumin level showed steeper decline 3 years before death in the died group than in the survived group. The difference in albumin between the died and survived groups became apparent 3 years before death (difference, 0.08 g/dL; 95% confidence interval, 0.00-0.15 g/dL; P = .04), and the difference widened over time (difference at 1 year before death, 0.24 g/dL; 95% confidence interval, 0.14-0.33 g/dL; P < .001). Furthermore, in an analysis of albumin trajectories according to cause of death, the albumin level showed a downward trend regardless of the cause of death.


      The serum albumin trajectory differed between patients undergoing hemodialysis who died and who survived, supporting the importance of monitoring the albumin trajectory in clinical practice.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Renal Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mancini A.
        • Grandaliano G.
        • Magarelli P.
        • Allegretti A.
        Nutritional status in hemodialysis patients and bioimpedance vector analysis.
        J Ren Nutr. 2003; 13: 199-204
        • Gurreebun F.
        • Hartley G.H.
        • Brown A.L.
        • Ward M.C.
        • Goodship T.H.
        Nutritional screening in patients on hemodialysis: is subjective global assessment an appropriate tool?.
        J Ren Nutr. 2007; 17: 114-117
        • Iseki K.
        • Kawazoe N.
        • Fukiyama K.
        Serum albumin is a strong predictor of death in chronic dialysis patients.
        Kidney Int. 1993; 44: 115-119
        • Kalantar-Zadeh K.
        • Kilpatrick R.D.
        • Kuwae N.
        • et al.
        Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction.
        Nephrol Dial Transplant. 2005; 20: 1880-1888
        • Fouque D.
        • Kalantar-Zadeh K.
        • Kopple J.
        • et al.
        A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.
        Kidney Int. 2008; 73: 391-398
        • Ikizler T.A.
        • Burrowes J.D.
        • Byham-Gray L.D.
        • et al.
        KDOQI clinical practice guideline for nutrition in CKD: 2020 update.
        Am J Kidney Dis. 2020; 76: S1-s107
        • Kotanko P.
        • Thijssen S.
        • Usvyat L.
        • et al.
        Temporal evolution of clinical parameters before death in dialysis patients: a new concept.
        Blood Purif. 2009; 27: 38-47
        • Usvyat L.A.
        • Barth C.
        • Bayh I.
        • et al.
        Interdialytic weight gain, systolic blood pressure, serum albumin, and C-reactive protein levels change in chronic dialysis patients prior to death.
        Kidney Int. 2013; 84: 149-157
        • van Walraven C.
        • Manuel D.G.
        • Knoll G.
        Survival trends in ESRD patients compared with the general population in the United States.
        Am J Kidney Dis. 2014; 63: 491-499
        • Nitta K.
        • Goto S.
        • Masakane I.
        • et al.
        Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality.
        Ren Replace Ther. 2020; 6: 41
        • Workgroup K.D.
        K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.
        Am J Kidney Dis. 2005; 45: 16-153
        • Farrington K.
        • Covic A.
        • Nistor I.
        • et al.
        Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR<45 mL/min/1.73 m2): a summary document from the European Renal Best Practice Group.
        Nephrol Dial Transpl. 2017; 32: 9-16
        • Liu J.
        • Huang Z.
        • Gilbertson D.T.
        • Foley R.N.
        • Collins A.J.
        An improved comorbidity index for outcome analyses among dialysis patients.
        Kidney Int. 2010; 77: 141-151
        • Kaup A.R.
        • Byers A.L.
        • Falvey C.
        • et al.
        Trajectories of depressive symptoms in older adults and risk of dementia.
        JAMA Psychiatry. 2016; 73: 525-531
        • Sabia S.
        • Dugravot A.
        • Dartigues J.F.
        • et al.
        Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.
        BMJ. 2017; 357: j2709
        • Newson Roger
        Attributable and unattributable risks and fractions and other scenario comparisons.
        Stata J. 2013; 13: 672-698
        • Beddhu S.
        • Kaysen G.A.
        • Yan G.
        • et al.
        Association of serum albumin and atherosclerosis in chronic hemodialysis patients.
        Am J Kidney Dis. 2002; 40: 721-727
        • Don B.R.
        • Kaysen G.
        Serum albumin: relationship to inflammation and nutrition.
        Semin Dial. 2004; 17: 432-437
        • Yelken B.M.
        • Gorgulu N.
        • Caliskan Y.
        • et al.
        Comparison of nutritional status in hemodialysis patients with and without failed renal allografts.
        Clin Transplant. 2010; 24: 481-487
        • Małgorzewicz S.
        • Debska-Slizień A.
        • Rutkowski B.
        • Lysiak-Szydłowska W.
        Serum concentration of amino acids versus nutritional status in hemodialysis patients.
        J Ren Nutr. 2008; 18: 239-247
        • Koppe L.
        • Fouque D.
        • Kalantar-Zadeh K.
        Kidney cachexia or protein-energy wasting in chronic kidney disease: facts and numbers.
        J Cachexia, Sarcopenia Muscle. 2019; 10: 479-484
        • Ikizler T.A.
        • Cano N.J.
        • Franch H.
        • et al.
        Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism.
        Kidney Int. 2013; 84: 1096-1107
        • de Mutsert R.
        • Grootendorst D.C.
        • Indemans F.
        • et al.
        Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition.
        J Ren Nutr. 2009; 19: 127-135
        • Austin S.R.
        • Wong Y.N.
        • Uzzo R.G.
        • Beck J.R.
        • Egleston B.L.
        Why summary comorbidity measures such as the charlson comorbidity index and elixhauser score work.
        Med Care. 2015; 53: e65-e72